Second chance: focused radiation for recurrent prostate cancer

NCT ID NCT03073278

Recruiting now Disease control Sponsor: Royal North Shore Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether a second, highly targeted dose of radiation (SBRT) can safely treat prostate cancer that has returned after initial radiation therapy. The study involves 36 men whose cancer is confined to a small area of the prostate. The main goal is to check for serious side effects and see if higher radiation doses are feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiotherapy (SBRT)
What this could lead to: If successful, this could offer a new treatment option for men whose prostate cancer returns after initial radiation, potentially controlling the disease without more invasive procedures.
What could go wrong: This is a very early, small feasibility trial (36 participants) focused on safety, not effectiveness. The risk of side effects from re-irradiation is unknown, and the approach may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY RECURRENT PROSTATE CANCER

Contacts and locations

Locations

Royal North Shore Hospital
RECRUITING

St Leonards, New South Wales, 2065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.